Bradley Haverkos
Overview
Explore the profile of Bradley Haverkos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allen J, Abbott D, Eskandar J, Bair S, Haverkos B, Jasem J, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Oct;
25(1):e26-e33.
PMID: 39426945
Background: Short diagnosis-to-treatment interval (DTI) is associated with high-risk disease and poor survival in diffuse large B-cell lymphoma (DLBCL). There is a paucity of literature on DTI and survival in...
2.
Kent A, Gil K, Jones M, Linden B, Purev E, Haverkos B, et al.
Transplant Cell Ther
. 2024 Aug;
PMID: 39154914
Despite the concurrent use of haploidentical cord (HCT) and dual cord (DCT) stem cell transplant approaches for over a decade, there have been few comparisons of their outcomes. Our objective...
3.
Colton M, Purev E, Haverkos B, Bair S, Jasem J, Jacob A, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jul;
24(11):778-782.
PMID: 39034202
Background: Chimeric antigen receptor (CAR) T-cell therapy has improved the historically poor outcomes for relapsed and refractory (R/R) large B-cell non-Hodgkin's lymphoma (LBCL). However, nearly 60% of patients will either...
4.
Wang T, Ahn K, Shadman M, Kaur M, Ahmed N, Bacher U, et al.
Leukemia
. 2024 May;
38(7):1564-1569.
PMID: 38750138
CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response...
5.
Bhansali R, Ellin F, Relander T, Cao M, Li W, Long Q, et al.
Blood Adv
. 2024 May;
8(13):3507-3518.
PMID: 38739715
Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS...
6.
Haverkos B, Zain J, Kamdar M, Neuwelt A, Davila E, Bradeen X, et al.
Blood Adv
. 2023 Dec;
8(3):708-711.
PMID: 38150586
No abstract available.
7.
Haverkos B, Alpdogan O, Baiocchi R, Brammer J, Feldman T, Capra M, et al.
Blood Adv
. 2023 Aug;
7(20):6339-6350.
PMID: 37530631
Lymphomas are not infrequently associated with the Epstein-Barr virus (EBV), and EBV positivity is linked to worse outcomes in several subtypes. Nanatinostat is a class-I selective oral histone deacetylase inhibitor...
8.
Stuver R, Horwitz S, Advani R, Vose J, Lee H, Mehta-Shah N, et al.
Br J Haematol
. 2023 May;
202(3):525-529.
PMID: 37217196
There remains no one standard induction for nodal-based peripheral T-cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as a novel induction strategy. Patients received CHOEP...
9.
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, et al.
Blood Adv
. 2023 May;
7(21):6381-6394.
PMID: 37171397
In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)-a rare category defined by high-grade morphologic features and...
10.
Jodon G, Colton M, Abbott D, Cai A, Haverkos B, Morgan R, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Nov;
23(1):49-56.
PMID: 36335021
Introduction: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of relapsed/refractory (R/R) B-cell lymphomas, though certain patients do not respond to treatment or relapse afterwards. The purpose of this...